Drug Sales Trends for cardizem la

Annual Sales Revenues and Units Sold for cardizem la

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
CARDIZEM LA			2021
CARDIZEM LA			2020
CARDIZEM LA			2019
CARDIZEM LA			2018
CARDIZEM LA			2017
CARDIZEM LA			2016
CARDIZEM LA			2015

Cardizem la Market Analysis and Financial Projection

Market Analysis and Sales Projections for CARDIZEM LA (Diltiazem)

Market Overview

CARDIZEM LA, a formulation of diltiazem hydrochloride, is a nondihydropyridine calcium channel blocker used primarily for the treatment of hypertension and improving exercise tolerance in patients with chronic stable angina. Here is a comprehensive analysis of the market and sales projections for this drug.

Market Size and Growth

The global diltiazem market, which includes CARDIZEM LA, is projected to experience significant growth. By 2028, the market is expected to reach US$ 832.51 million from US$ 369.95 million in 2021, growing at a Compound Annual Growth Rate (CAGR) of 12.3% from 2021 to 2028[1][3].

In North America specifically, the diltiazem market is anticipated to grow from US$ 161.53 million in 2021 to US$ 369.22 million by 2028, with a CAGR of 12.5% during the same period[3].

Key Drivers of Market Growth

Increase in Cardiovascular Disease Incidence

The rising incidence of cardiovascular diseases, particularly among the elderly population, is a major driver of the diltiazem market. Cardiovascular diseases such as hypertension, angina, and atrial fibrillation are more prevalent in older adults due to structural and functional changes in the cardiovascular system associated with aging[1][3].

Increasing Elderly Population

The global elderly population is projected to increase significantly, leading to a higher incidence of cardiovascular diseases. This demographic shift is expected to bolster the demand for diltiazem and other cardiovascular medications[1][3].

Prevalence of Atrial Fibrillation

The increasing prevalence of atrial fibrillation worldwide also drives the demand for diltiazem. Diltiazem is effective for initial ventricular rate control in patients with atrial fibrillation, making it a crucial medication in this context[1].

Market Segments

Product Type

The diltiazem market is segmented into capsules, injections, and tablets. In 2021, the tablets segment held the largest share of the market. However, the capsules segment is expected to witness the fastest CAGR during the forecast period from 2021 to 2028[1][3].

Application

The market is also segmented by application, with hypertension being the largest segment in 2021. The angina segment is expected to grow at the fastest CAGR in the coming years[3].

Competitive Landscape

The diltiazem market is competitive, with several key players including Bausch Health, Teva Pharmaceutical Industries Ltd, Mylan N.V, Athenex, Pfizer, Inc, Glenmark, Sandoz (Novartis Ag), Sun Pharmaceutical Company Ltd, Hikma Pharmaceuticals, and Zydus Pharmaceuticals among others[1].

Historical Anticompetitive Practices

In the past, there have been instances of anticompetitive practices affecting the market. For example, Hoechst Marion Roussel (now Aventis Pharmaceuticals, Inc) was involved in a consent agreement with the FTC to resolve allegations of delaying the entry of generic versions of Cardizem CD through payments to Andrx Corporation[2].

Product Profile: CARDIZEM LA

Pharmacology

CARDIZEM LA works by inhibiting the calcium ion influx during membrane depolarization in cardiac and smooth muscle, leading to a decrease in heart rate and systemic blood pressure. This action results in increased exercise tolerance and decreased myocardial oxygen demand[4][5].

Clinical Studies

Clinical studies have shown that CARDIZEM LA is effective in treating hypertension and improving exercise tolerance in patients with chronic angina. A randomized, double-blind, parallel-group, dose-response trial demonstrated that evening doses of CARDIZEM LA increased exercise tolerance significantly compared to placebo[4].

Contraindications and Side Effects

While CARDIZEM LA is generally well-tolerated, it can have side effects such as lower limb edema, dizziness, and fatigue. The drug is contraindicated in certain conditions, and its use must be carefully managed to minimize adverse effects[4][5].

Impact of COVID-19

The COVID-19 pandemic has had a positive impact on the diltiazem market, as the global healthcare system has focused on developing and distributing essential medications, including those for cardiovascular diseases. This has led to increased demand and production of diltiazem formulations[3].

Future Trends and Developments

The market is expected to see continued growth driven by increasing government initiatives for healthcare promotion, advancements in drug delivery systems, and the rising need for effective cardiovascular treatments. However, the market may face challenges due to the side effects associated with diltiazem and potential competition from new or generic formulations[1][3].

Key Takeaways

• The global diltiazem market is projected to grow significantly, driven by the increasing incidence of cardiovascular diseases and the rising elderly population.
• CARDIZEM LA is a key formulation in this market, used for treating hypertension and angina.
• The market is segmented by product type and application, with tablets currently holding the largest share.
• The capsules segment is expected to grow at the fastest CAGR.
• Historical anticompetitive practices have affected market dynamics, but current regulations aim to prevent such practices.
• The COVID-19 pandemic has positively impacted the market by increasing the focus on essential medications.

Frequently Asked Questions (FAQs)

1. What is CARDIZEM LA used for?

CARDIZEM LA is used for the treatment of hypertension and improving exercise tolerance in patients with chronic stable angina[5].

2. What are the key drivers of the diltiazem market growth?

The key drivers include the increasing incidence of cardiovascular diseases and the rising elderly population[1][3].

3. How does CARDIZEM LA work?

CARDIZEM LA works by inhibiting the calcium ion influx during membrane depolarization in cardiac and smooth muscle, leading to a decrease in heart rate and systemic blood pressure[4][5].

4. What are the common side effects of CARDIZEM LA?

Common side effects include lower limb edema, dizziness, and fatigue[4].

5. How has the COVID-19 pandemic affected the diltiazem market?

The COVID-19 pandemic has had a positive impact on the market by increasing the focus on essential medications, including those for cardiovascular diseases[3].

Cited Sources:

1. The Insight Partners. Diltiazem Market Size, Share & Growth Analysis by 2028.
2. Federal Trade Commission. Consent Agreement Resolves Complaint Against Pharmaceutical Companies Hoechst Marion Roussel Inc.
3. Business Market Insights. Diltiazem Market in North America report 2028.
4. Pharmacy Times. RxPRODUCT NEWS: PROFILE: Cardizem LA (diltiazem).
5. DailyMed. CARDIZEM LA- diltiazem hydrochloride tablet, extended release.